Hexin Medical Technology Co., Ltd, a radionuclide therapy developer based in Suzhou, has reportedly raised over RMB 100 million (USD 14.5 million) in a Series A financing round. The round was led by Cowin Capital and Sunland Fund, with participation from Yishang Huicheng (Beijing) Investment. The proceeds will be used to accelerate the clinical development of multiple tumor diagnosis and treatment-integrated products, as well as to expand the company’s product pipeline.
Company Background and Technology
Founded in 2020, Hexin Medical Technology (Hexin Med) boasts first-in-class dual-target radiation integrated diagnosis and treatment patented technology. The company’s lead product, 68Ga-HX01, is currently at the Phase I clinical stage. This innovative approach to radionuclide therapy positions Hexin Med at the forefront of oncology treatment and diagnosis.
Upcoming Trials and Commercialization
In addition to the ongoing development of 68Ga-HX01, Hexin Med expects to conduct an investigator-initiated trial (IIT) for its Category 1 177Lu dual-target therapy in the first half of this year. The company anticipates the first product commercialization in 2025, marking a significant milestone in bringing its advanced radionuclide therapies to market.
Future Prospects
The Series A financing round is a crucial step for Hexin Medical Technology, providing the necessary capital to advance its clinical programs and expand its product offerings. With a focus on innovative radionuclide therapies, Hexin Med is well-positioned to make a significant impact in the field of oncology, offering new treatment options for patients with various types of cancer. This investment not only supports the company’s growth but also highlights the potential of radionuclide therapy in the global healthcare market.-Fineline Info & Tech
